ClinicalTrials.gg
RecruitingNCT07743944VERITASUpdated Aug 4, 2026

A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

An observational study in Breast Cancer, sponsored by AstraZeneca. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by AstraZeneca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Breast Neoplasms by AstraZeneca — 20 open to participants now, 50 under way, 24 of them phase 3. Breast Neoplasms · AstraZeneca.

Planned enrollment
9th of 72
2,000 · median 508
Started
2026
with 6 others
Observational
72 of 198
11 open now
Primary completion
2031-08
later than 48 of 49 live
Registered
197th of 198
by date

Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 9th largest by planned enrollment of the 72 observational ones that give a count, is one of 7 that started in 2026, is one of 72 observational ones, reaches primary completion later than 48 of the 49 other live ones, and was the 197th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 198 studies in Breast Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The study aims to describe demographics, clinical characteristics, genetic test diagnosis, treatment patterns, and clinical outcomes in HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null) unresectable or metastatic breast cancer patients in China; and exploratory describe clinical outcomes by treatment regimens, also report the QoL and other patient-report outcomes (PRO) and to assess healthcare resource utilization (HCRU) and costs overall and by LoT.

Read the detailed description

The study consists of both retrospective and prospective components, defined relative to the index date.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Metastatic Breast Cancer
  • HR-Positive
  • HER2-Negative
  • Real-world data
  • Observational Study
  • Treatment Patterns
  • China
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes Chinese adult patients with HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null) unresectable or metastatic breast cancer who are about to initiate 2L systemic therapy or initiated 2L systemic therapy within 2 months at participating sites.

Eligibility criteria

Inclusion Criteria * Must be competent and able to comprehend, sign, and date an Institutional Review Board or Institutional Ethics Committee approved form (ICF) before participating in the study. OR Eligible for exemption from informed consent (for patients who die or became lost to follow-up within 2 months of initiating 2L therapy). * Chinese men or women ≥ 18 years old at time of consent. * documented breast cancer that: a) is unresectable or . b) is HR+/- (IHC 2+/ISH- or IHC 1+ or IHC 0, with/without membrane staining) based on the most recent test result * Planning to initiate 2L treatment or initiated 2L systemic therapy within 2 months prior enrollment as per the prescription or medical records. Exclusion Criteria * Patients who plan to participate in any blinded interventional clinical trial in 2L setting.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with HR+/HER2- unresectable or metastatic breast cancer

    The study will include adult patients with HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null) unresectable or metastatic breast cancer who plan to initiate second-line (2L) systemic therapy or initiated 2L systemic therapy within 2 months.

06

What researchers measure

Primary outcomes

  1. Percentage of patients receiving different regimens in each Line of treatment (LoT)

    Percentage of participants receiving each systemic regimen within a given LoT.

    Time frame: From baseline up to 5 years

  2. Percentage of participants receiving different treatment sequence across LoTs

    Percentage of participants receiving different treatment sequence among those who entered the subsequent LoT.

    Time frame: From baseline up to 5 years

  3. The attrition rate after each Line of Treatment (LoT)

    Among participants with a documented therapy end for a given LoT, the percentage who did not initiate the next LoT.

    Time frame: From baseline up to 5 years

Secondary outcomes

  1. Biomarker and Genetic Testing Pattern

    Metrics include percentage of participants who undergo testing per biomarker/mutation within each LoT, testing timing, specimen type, assay method, and result distribution.

    Time frame: From baseline up to 5 years

  2. Demographic characteristics

    Metrics include descriptive statistics for age and counts for categorical variables

    Time frame: At baseline

  3. Percentage of Participants with AEs, TRAEs, and SAEs

    Proportion of participants with AEs, TRAEs, and SAEs, by MedDRA SOC/PT and CTCAE v6.0 grade; proportions with AEs leading to dose modification, discontinuation, or death. Includes suspected drug, AE dates, seriousness, causality, and outcomes.

    Time frame: From baseline up to 5 years

  4. Clinical management of adverse events of special interest

    Metrics include percentage of participants who underwent diagnostic tests, prophylactic medications, therapeutic medications, dose modifications of treatment regimens, and follow-up assessments.

    Time frame: From baseline up to 5 years

  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS)

    Percentage of participants with different ECOG PS

    Time frame: At baseline

  6. ER/PR status

    Percentage of participants with different ER (estrogen receptor) and PR (progesterone receptor) status

    Time frame: At baseline

  7. HER2 status

    Percentage of participants with different HER2 (human epidermal growth factor receptor 2) status

    Time frame: At baseline

  8. TNM stage at diagnosis

    Percentage of participants with different Tumor (T), Node (N), Metastasis (M) stage at diagnosis

    Time frame: At baseline

  9. Endocrine resistance

    Percentage of participants with different endocrine resistance status

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)
    Nanjing, Jiangsu 210029, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2031, 59 months later.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 59 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Aug 4, 2026
StartEst.
Aug 5, 2026
Primary completionEst.
Aug 4, 2031
CompletionEst.
Aug 4, 2031
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07743944
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Aug 5, 2026 (estimated)
Primary completion
Aug 4, 2031 (estimated)
Completion
Aug 4, 2031 (estimated)
Last update
Aug 4, 2026

Study contacts

Astra Zeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion